.jpeg)
培米替尼引发的除了眼睛病变以及高磷血症以外的不良反应怎么处理？
Other treatments caused by pemetinib
Pemetinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with rearrangements detected by fibroblast growth factor receptor 2 (FGFR2) fusion or other FDA-approved assays. In addition to eye lesions and hyperphosphatemia, pemetinib may also cause other adverse reactions, in which case the dose of pemetinib needs to be adjusted.
When patients experience grade 3 other adverse reactions with pemetinib, pemetinib is withheld until it decreases to grade 1 or baseline. If resolution occurs within 2 weeks, resume pemetinib at the next lower dose. If pemetinib does not resolve within 2 weeks, permanently discontinue the drug. After 2 dose reductions, pemetinib was permanently discontinued for grade 3 relapse; when the patient experienced grade 4 other adverse reactions with pemetinib, pemetinib was permanently discontinued.
Pemetinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements detected by other FDA-approved assays; and for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLN) associated with fibroblast growth factor receptor 1 (FGFR1) rearrangements.
When treating cholangiocarcinoma, the recommended dose of pemetinib is 13.5 mg, taken orally once daily for 14 days, followed by 7 days off, for a total cycle of 21 days. Continue treatment until disease progression or unacceptable toxicity.
The recommended dose of pemetinib for the treatment of FGFR1-rearranged myeloid/lymphoid neoplasms is 13.5 mg orally once daily. Continue treatment until disease progression or unacceptable toxicity.
Take it at approximately the same time every day (with or without food) and swallow the tablet whole. Do not crush, chew, split or dissolve tablets. If the patient does not take pemetinib on time for 4 hours or more, or vomits, continue taking the drug at the next planned dose. It is recommended that patients take medication under the guidance of a doctor. For more details, please read the drug instructions.
Recommended related articles:
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
